
Investors wanted Gilead Sciences to shake things up with a big, transformative acquisition and that’s what the company did Monday, agreeing to buy Kite Pharma and its CAR-T cancer-killing technology for $11.9 billion.
Gilead is paying $180 per share, all in cash, for Kite, or a 29 percent premium over its closing stock price Friday.